US Stock Insider Trading | Illumina disclosed 5 insider transactions on February 18

K-LinePoet · 2026-02-19T03:39:35+00:00

On February 18, 2026, Illumina disclosed five insider transactions, with Director Thaysen Jacob selling 6,544 shares. Executives such as Wedel, Davies, Leckman, and others also conducted multiple stock sales at an approximate price of $116.51, reflecting internal trading activity within the company.

K-LinePoet

2026-02-19 03:39:35

Abstract generation in progress

On February 18, 2026, Illumina (ILMN) disclosed five insider trading transactions. Director Thaysen Jacob sold 6,544 shares.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Executive	Wedel Christensen Jakob	February 15, 2026	Sell	578	116.51	$67,300
February 18, 2026	Executive	Davies Scott M	February 15, 2026	Sell	1,037	116.51	$120,800
February 18, 2026	Executive	Leckman Patricia	February 15, 2026	Sell	1,304	116.51	$151,900
February 18, 2026	Director	Thaysen Jacob	February 15, 2026	Sell	6,544	116.51	$762,400
February 18, 2026	Executive	Leckman Patricia	February 18, 2026	Sell	2,370	116.18	$275,300
February 17, 2026	Executive	Leckman Patricia	February 12, 2026	Sell	424	114.44	$48,500
February 17, 2026	Executive	Davies Scott M	February 12, 2026	Sell	550	114.44	$62,900
February 17, 2026	Executive	Barnard Steven	February 12, 2026	Sell	1,014	114.44	$116,000
February 17, 2026	Director	Thaysen Jacob	February 12, 2026	Sell	5,470	114.44	$626,000
February 17, 2026	Executive	Pegels Kevin Carl	February 12, 2026	Sell	874	114.44	$100,000

[Company Profile]

Illumina, Inc. is a leading developer, manufacturer, and seller of life sciences tools and integrated systems for analyzing genetic variation and gene function. The company was incorporated in California in April 1998 and completed a reorganization in Delaware in July 2000. Using patented technology, the company offers a range of genetic analysis solutions and products for highly interconnected markets, including gene sequencing, genotyping, gene expression, and molecular diagnostics. Its customers include leading genomics research centers, academic institutions, government laboratories, clinical research organizations, as well as pharmaceutical companies, biotech firms, agricultural genomics R&D companies, and client genome testing companies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes